about
Mutation of the gene encoding human TTF-2 associated with thyroid agenesis, cleft palate and choanal atresia15 YEARS OF PARAGANGLIOMA: Clinical manifestations of paraganglioma syndromes types 1-5Histone H2B monoubiquitination: roles to play in human malignancyImmunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromesImmunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct typesLeukocyte matrix metalloproteinase-9 is elevated and contributes to lymphocyte activation in type I diabetes.A preoperative nomogram for the prediction of ipsilateral central compartment lymph node metastases in papillary thyroid cancer.Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CT.Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma.Current and emerging therapies for advanced adrenocortical carcinoma.Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants.Proteomics of thyroid tumours provides new insights into their molecular composition and changes associated with malignancy.Fumarate Hydratase-deficient Uterine Leiomyomas Occur in Both the Syndromic and Sporadic Settings.Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.Succinate dehydrogenase deficiency is rare in pituitary adenomas.Identification of Wnt family inhibitors: a pituitary tumor directed whole genome approach.Multikinase inhibitors: a new option for the treatment of thyroid cancer.Effects of vitamin D in skeletal muscle: falls, strength, athletic performance and insulin sensitivity.TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas.Increased SSTR2A and SSTR3 expression in succinate dehydrogenase-deficient pheochromocytomas and paragangliomas.Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours.The RING finger domain E3 ubiquitin ligases BRCA1 and the RNF20/RNF40 complex in global loss of the chromatin mark histone H2B monoubiquitination (H2Bub1) in cell line models and primary high-grade serous ovarian cancer.Disease Progression in Papillary Thyroid Cancer with Biochemical Incomplete Response to Initial Therapy.The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer.Destabilizing RET in targeted treatment of thyroid cancers.Therapeutic options in papillary thyroid carcinoma: current guidelines and future perspectives.Association Between Heart Rate Variability Measures and Blood Glucose Levels: Implications for Noninvasive Glucose Monitoring for Diabetes.Phosphoproteomics of MAPK inhibition in BRAF-mutated cells and a role for the lethal synergism of dual BRAF and CK2 inhibition.Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas.Vitamin D signaling regulates proliferation, differentiation, and myotube size in C2C12 skeletal muscle cells.NRASQ61R Mutation-specific Immunohistochemistry Also Identifies the HRASQ61R Mutation in Medullary Thyroid Cancer and May Have a Role in Triaging Genetic Testing for MEN2.BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.Pheo-Type: A Diagnostic Gene-expression Assay for the Classification of Pheochromocytoma and Paraganglioma.DEFLATE compression algorithm corrects for overestimation of phylogenetic diversity by Grantham approach to single-nucleotide polymorphism classification.Utility of the succinate: Fumarate ratio for assessing SDH dysfunction in different tumor types.Somatic Mutations of FOXE1 in Papillary Thyroid Cancer.Analysis of SDHAF3 in familial and sporadic pheochromocytoma and paraganglioma.Comprehensive analyses of somatic TP53 mutation in tumors with variable mutant allele frequency.
P50
Q24322560-701C1EC9-9F21-4128-8A02-4CC7197B199AQ26798384-F8062FCF-C8C3-4773-9619-ADE18BDABC60Q26825542-93BB2F5E-3C8C-4317-BAF1-B4A23F03D35BQ28276252-15BB20FB-8C6A-48F8-882F-6C912C53EFBDQ28277229-C80829BC-43A0-4BB9-8637-E41A2AE0C202Q33220680-225D0759-5021-49D2-A8D6-CD059A6092A4Q33440071-B578E2B4-C4F2-4839-91B6-EA5522FD96E4Q34321242-673E02C5-EE11-4F5B-BE24-32838C247FB3Q34716574-9E82A0B5-1BA8-4AFB-8295-D5B6D2CE020FQ35558293-CBCBD58F-9D13-45DA-921F-858D1067BB07Q35584305-25CBCDBE-26EB-4282-88CA-8CC88996FF98Q36431628-A093F367-737B-42EF-ADF7-40231DA68150Q36741317-79B8DB9D-64B2-410B-B48A-CDF41BFB4D07Q36795608-92088573-064B-4330-9A6E-C0372F998819Q36910793-708032A3-121F-489E-B531-AC5AA3FE12ACQ37216703-F4270411-118C-4EB6-BB3D-1D4A5A052840Q37665939-6A720F84-4514-4C81-91D9-98DBB22BA100Q37704679-792B7E06-8C3B-4DF1-A479-A914A586EAC8Q37921602-A2926C8B-E512-4C86-9EC5-E4EB9C3F5DCBQ38164434-8A163FF7-D376-42C8-86F5-A712DC885F75Q38383121-38101598-D256-4673-8E6A-5CE269BEF220Q38388495-CE214ABA-F153-4F8F-B05E-A60339BFB49BQ38423703-B0AD503A-0249-4BBF-88D1-DBD4E3DA7D29Q38734927-35B88882-5BE7-49AB-AABB-41ED2AB0A4ADQ38741579-001F5F8F-C419-401B-9C66-CCE44F50B08BQ38743211-A8059E28-D76A-49D7-951D-6FE21ABF4771Q38819099-0067B5AA-048D-4EB9-B42F-8D81E2844788Q38844362-A91973C2-B904-4B71-B813-941378DF39C3Q38858622-0FA1AA7E-B606-46D6-9C41-EF5326971C69Q38995187-43F3E23A-0A98-4C9F-B6E8-4A281B292679Q39011468-7EFEFFCB-2BCD-4361-8962-5EC3684E5130Q39054183-93CBFDE2-0E6A-4DC0-953C-244C834E5FD1Q39382179-4EB62E9B-1272-40ED-8B39-7A874F48A380Q39800644-610090F4-DDD8-4194-A11F-29ACEE61F1A2Q40076677-38E8A779-B06F-4F00-8553-05FC543583FCQ40711328-056BACE6-47DD-4BD5-9A7B-319B98F31F66Q40946328-75703FC0-44F9-4F9A-A5A3-5FDD31C340BCQ40965423-BFE887EF-681C-4112-92B0-8B6EC45AE11EQ41111757-7B135122-598B-4734-83F3-895FE534893FQ41613769-C0FAA24F-12CF-44E0-A7BC-8EF0C3D79B99
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Roderick J Clifton-Bligh
@ast
Roderick J Clifton-Bligh
@en
Roderick J Clifton-Bligh
@es
Roderick J Clifton-Bligh
@nl
type
label
Roderick J Clifton-Bligh
@ast
Roderick J Clifton-Bligh
@en
Roderick J Clifton-Bligh
@es
Roderick J Clifton-Bligh
@nl
altLabel
Roderick Clifton-Bligh
@en
prefLabel
Roderick J Clifton-Bligh
@ast
Roderick J Clifton-Bligh
@en
Roderick J Clifton-Bligh
@es
Roderick J Clifton-Bligh
@nl
P106
P1153
6602549172
P31
P496
0000-0002-1545-0368